Partners

BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS (GREECE)

ZORA BIOSCIENCES LTD (FINLAND)

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (GERMANY)

COMPREHENSIVE BIOMARKER CENTER GMBH (GERMANY)

BIOVISTA (GREECE)

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UK)

TAMPEREEN YLIOPISTO (FINLAND)

UNIVERSITA DEGLI STUDI DI MILANO (ITALY)

UNIVERSITAET ZUERICH (SWITZERLAND)

SYNLAB HOLDING GMBH (GERMANY)

GENOWAY S.A. (FRANCE)

CHARITE - UNIVERSITAETSMEDIZIN BERLIN (GERMANY) - NEW PARTNER

For partner descriptions and contact details please scan here or visit **http://www.riskycad.eu/index.php/aboutus/partner-institutions**

About RiskyCAD

RiskyCad is an FP7 European Collaborative network that takes advantage of the latest technologies and some of the finest European cohorts to improve risk prediction in asymptomatic patients with high risk of CAD.

Through the assembly of an interdisciplinary group of academic researchers and commercial entreprises, with an excellent track record in cohort-based studies, laboratory medicine and omics technologies, RiskyCad aims to identify new biomarkers, develop new diagnostic tests, improve current risk estimation models, and provide new treatments based on drug repositioning for apparently asymptomatic patients that are in high risk of CAD.



www.powergraphics.gr

Contact

Dr. Evangelos Andreakos
(Coordinator)
Email: vandreakos@bioacademy.gr

Dr. Christos Ilioudis
(Project Manager)
Email: cilioudis@bioacademy.gr

Further information:
www.riskycad.eu

RiskyCad

Personalized Diagnostics and Treatment of High Risk Coronary Artery Disease Patients

This project has received funding from the European Union's Seventh Framework Programme for Research, Technological Development and Demonstration under Grant Agreement 305739

SEVENTH FRAMEWORK PROGRAMME

European Union

Motivation

Coronary artery disease (CAD) has been established as a major epidemic of our time requiring immediate action for the development of novel preventive and/or therapeutic strategies for its management.

To identify patients in high risk of developing CAD and in most need for primary prevention treatment, traditional approaches based on clinical diagnosis, laboratory and imaging data have been used.

However, these diagnostic approaches and scoring systems do not adequately stratify CAD patients according to risk and do not properly support clinical decision, resulting in under-treatment and unfocused use of limited health care resources.

RiskyCAD has been set with the aim to advance the accurate diagnosis of coronary artery disease (CAD), identify high risk patients and improve primary prevention of CAD by developing novel therapeutics and tailoring treatment to best match the individual patient's profile.



Figure: The project explained. RiskyCAD aims at developing novel diagnostic tools and treatments to enhance personalized medicine of high risk coronary artery disease (CAD) patients.

Objectives

To build on earlier observations for patient stratification, identify novel biomarkers for CAD, and develop new diagnostic tools and "personalized" therapeutic strategies, RiskyCAD partners have agreed on the following objectives:

1) To identify molecular lipid and miRNA biomarkers for CAD and use them in combination with existing risk models and other biomarker candidates to improve the identification of high risk CAD patients

2) To unwind the mechanistic links between disease risk and biomarkers, and investigate rational therapeutic approaches

3) To develop novel diagnostic and therapeutic strategies based on patient stratification and drug repositioning.

Strategy

The project follows three interconnected workflows: models, mechanisms and translational output. Models are designed to test the hypothesis, identify mechanisms and subsequently evaluate translational outputs. They include some of the finest cohorts for the study of CAD, reprogrammed iPS cells as a new human model of CAD and mouse models of CAD some of which will be generated during the project.

RiskyCAD: Interactions between Partners per WP



Consortium

The Consortium is an integrative European effort of cardiologists, lipidologists, clinical and basic immunologists, biotechnologists, molecular biologists, bioinformaticians and computational biologists with a strong track record.

The partners have been carefully selected to provide all necessary expertise and achieve a significant number of scientific breakthroughs of high translational value.

The partners cover the full geographic spectrum of the EU by being located in the following countries: Finland, France, Germany, Greece, Italy, Switzerland and United Kingdom.

Impact

RiskyCAD aims at improving health and quality of life of individuals at high risk of developing CAD, and already affected individuals, by filling in critical gaps of knowledge that exist in the stratification of CAD patients, the diagnosis of the ones in high risk, and the availability of current therapeutic options.

RiskyCAD further aims at exploiting European research strengths in biomarker and cardiovascular research to boost European health-related industries and businesses, in a rapidly increasing but highly competitive global market. This is expected to profoundly impact future patient care, reduce health care costs and support local industries to improve their pipeline.